139 related articles for article (PubMed ID: 17698328)
1. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD.
Trzepacz PT; Williams DW; Feldman PD; Wrishko RE; Witcher JW; Buitelaar JK
Eur Neuropsychopharmacol; 2008 Feb; 18(2):79-86. PubMed ID: 17698328
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.
Michelson D; Read HA; Ruff DD; Witcher J; Zhang S; McCracken J
J Am Acad Child Adolesc Psychiatry; 2007 Feb; 46(2):242-51. PubMed ID: 17242628
[TBL] [Abstract][Full Text] [Related]
3. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
[TBL] [Abstract][Full Text] [Related]
5. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
Wilens TE; Newcorn JH; Kratochvil CJ; Gao H; Thomason CK; Rogers AK; Feldman PD; Levine LR
J Pediatr; 2006 Jul; 149(1):112-9. PubMed ID: 16860138
[TBL] [Abstract][Full Text] [Related]
6. Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity.
ter Laak MA; Temmink AH; Koeken A; van 't Veer NE; van Hattum PR; Cobbaert CM
Pediatr Neurol; 2010 Sep; 43(3):159-62. PubMed ID: 20691935
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
; Bangs ME; Emslie GJ; Spencer TJ; Ramsey JL; Carlson C; Bartky EJ; Busner J; Duesenberg DA; Harshawat P; Kaplan SL; Quintana H; Allen AJ; Sumner CR
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):407-20. PubMed ID: 17822337
[TBL] [Abstract][Full Text] [Related]
9. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
Biederman J; Gao H; Rogers AK; Spencer TJ
Biol Psychiatry; 2006 Nov; 60(10):1106-10. PubMed ID: 16806096
[TBL] [Abstract][Full Text] [Related]
10. Atomoxetine for attention deficit hyperactivity disorder in mental retardation.
Fernández-Jaén A; Fernández-Mayoralas DM; Calleja Pérez B; Muñoz Jareño N; Campos Díaz Mdel R
Pediatr Neurol; 2010 Nov; 43(5):341-7. PubMed ID: 20933178
[TBL] [Abstract][Full Text] [Related]
11. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder.
Newcorn JH; Michelson D; Kratochvil CJ; Allen AJ; Ruff DD; Moore RJ;
Pediatrics; 2006 Dec; 118(6):e1701-6. PubMed ID: 17101710
[TBL] [Abstract][Full Text] [Related]
12. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
Wernicke JF; Kratochvil CJ
J Clin Psychiatry; 2002; 63 Suppl 12():50-5. PubMed ID: 12562062
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy with atomoxetine for US children and adolescents.
Bhatara VS; Aparasu RR
Ann Clin Psychiatry; 2007; 19(3):175-80. PubMed ID: 17729019
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.
Brown JT; Bishop JR
Pharmacogenomics; 2015; 16(13):1513-20. PubMed ID: 26314574
[TBL] [Abstract][Full Text] [Related]
15. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
Chalon SA; Desager JP; Desante KA; Frye RF; Witcher J; Long AJ; Sauer JM; Golnez JL; Smith BP; Thomasson HR; Horsmans Y
Clin Pharmacol Ther; 2003 Mar; 73(3):178-91. PubMed ID: 12621383
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD.
Adler L; Dietrich A; Reimherr FW; Taylor LV; Sutton VK; Bakken R; Allen AJ; Kelsey D
Ann Clin Psychiatry; 2006; 18(2):107-13. PubMed ID: 16754416
[TBL] [Abstract][Full Text] [Related]
17. A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).
Ramoz N; Boni C; Downing AM; Close SL; Peters SL; Prokop AM; Allen AJ; Hamon M; Purper-Ouakil D; Gorwood P
Neuropsychopharmacology; 2009 Aug; 34(9):2135-42. PubMed ID: 19387424
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
19. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.
Brown JT; Abdel-Rahman SM; van Haandel L; Gaedigk A; Lin YS; Leeder JS
Clin Pharmacol Ther; 2016 Jun; 99(6):642-50. PubMed ID: 26660002
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder.
Witcher JW; Long A; Smith B; Sauer JM; Heilgenstein J; Wilens T; Spencer T; Biederman J
J Child Adolesc Psychopharmacol; 2003; 13(1):53-63. PubMed ID: 12804126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
